Objective: To observe the inhibitory effect of auricular concha transcutaneous electrostimulation (ACTES) of different frequencies and duration on acute seizures in epilepsy rats so as to select a better stimulating parameter for relieving epilepsy.

Methods: According to the stimulation duration of ACTES, 44 Sprague-Dawley rats were randomized into: 30 s, 5 min, 10 min, and 30 min groups. Epilepsy model was duplicated by intraperitoneal injection of PTZ (pentylenetetrazol, 50 mg/kg). Cerebral field potentials delivered from the fixed 4 recording electrodes array (A-P: -3 -6, L: 4 - 6, H: 1. 5) and reference electrode (a fixed screw) touching the cerebral dura surface were recorded using a data acquisition system (Cerebus 5.0 system). Transcutaneous electrostimulation (1 mA, duration 500 micro(s)) of frequency 2 Hz, 20 Hz and 100 Hz was applied to auricular concha by using an electric stimulator. The anti-epileptic effects of ACTES were evaluated by using the duration and rate of seizure suppression.

Results: (1) The anti-epileptic effect of 20 Hz -ACTES was markedly longer than those of 2 Hz and 100 Hz in the duration of seizure suppression (P < 0.05). (2) After 2 Hz-ACTES, the anti-epileptic effects (duration and inhibitory rate) in 30 s-stimulation group were markedly longer than those of the 5 min-, 10 min- and 30 min-stimulation groups (P < 0.01, P < 0.05). (3) After 100 Hz-ACTES, the anti-epileptic effects (duration and rate of seizure suppression) in the 30 min-stimulation group were markedly longer than those in the 30 s-, 5 min- and 10 min-stimulation group (P < 0.01, P < 0.05).

Conclusion: ACTES at 20 Hz can effectively lessen epileptic seizures, and under fixed stimulating frequencies of 2 Hz and 100 Hz, the anti-epileptic effects of 30 s ACTES and 30 min-ACTES are obviously better in epilepsy rats.

Download full-text PDF

Source

Publication Analysis

Top Keywords

anti-epileptic effects
16
transcutaneous electrostimulation
12
auricular concha
12
markedly longer
12
stimulating frequencies
8
duration
8
frequencies duration
8
duration acute
8
acute seizures
8
seizures epilepsy
8

Similar Publications

Chronic intraoral neuropathic pain (NP), often developing post-dental procedures, poses significant management challenges. The prevalent use of systemic treatments, with their frequent substantial side effects, emphasizes the need for alternative therapeutic strategies. Our aim is to explore the efficacy and adherence with a topical drug regimen delivered through a neurosensory stent (NS) for treating chronic neuropathic pain (NP) within the oral cavity.

View Article and Find Full Text PDF

The primary objective of this study was to examine neurological disorders and cognitive impairments in patients with secondary hypothyroidism and epilepsy undergoing treatment with antiepileptic medications. The study included 184 patients divided into three groups: Group 1 (subclinical hypothyroidism, n = 60), Group 2 (manifest hypothyroidism, n = 64), and Group 3 (control, n = 60). Patients in Group 2 received levothyroxine therapy (initial dose of 25 μg/day, titrated to 50-100 μg/day), while Groups 1 and 2 were treated with anti-seizure medications (valproic acid, 40 mg/kg/day).

View Article and Find Full Text PDF

: Objective: To discuss therapeutic outcomes in patients with symptomatic near-narrow internal auditory canal (NNIAC). : We retrospectively analyzed the records of 26 symptomatic patients diagnosed with NNIAC, who had been treated with anti-epileptic drugs. In addition to clinical and radiological data, we recorded I-III latencies of auditory brainstem responses prior to and after medical therapy.

View Article and Find Full Text PDF

Differential Inhibition by Cenobamate of Canonical Human Nav1.5 Ion Channels and Several Point Mutants.

Int J Mol Sci

January 2025

Department of Anatomy, Animal Physiology and Biophysics, Faculty of Biology, University of Bucharest, Splaiul Independentei 91-95, 050095 Bucharest, Romania.

Cenobamate is a new and highly effective antiseizure compound used for the treatment of adults with focal onset seizures and particularly for epilepsy resistant to other antiepileptic drugs. It acts on multiple targets, as it is a positive allosteric activator of γ-aminobutyric acid type A (GABA) receptors and an inhibitor of neuronal sodium channels, particularly of the late or persistent Na current. We recently evidenced the inhibitory effects of cenobamate on the peak and late current component of the human cardiac isoform hNav1.

View Article and Find Full Text PDF

Background: Paliperidone is a second-generation antipsychotic and the main active metabolite of risperidone, formulated to provide consistent therapeutic effects through an extended-release system, designed to provide consistent therapeutic effects through an extended-release formulation. While commonly used in clinical practice, switching from risperidone to paliperidone, particularly during valproate therapy, can pose challenges due to potential pharmacokinetic interactions that may increase the risk of extrapyramidal symptoms (EPS). Despite clinical observations suggesting these interactions, case reports documenting such adverse effects are scarce.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!